GB2215205A - Skin treatment formulations comprising boric acid and/or perborate salt - Google Patents
Skin treatment formulations comprising boric acid and/or perborate salt Download PDFInfo
- Publication number
- GB2215205A GB2215205A GB8804531A GB8804531A GB2215205A GB 2215205 A GB2215205 A GB 2215205A GB 8804531 A GB8804531 A GB 8804531A GB 8804531 A GB8804531 A GB 8804531A GB 2215205 A GB2215205 A GB 2215205A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formulation according
- formulation
- salt
- perborate
- boric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000009472 formulation Methods 0.000 title claims abstract description 32
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 239000004327 boric acid Substances 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 title claims abstract description 7
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 6
- XQSBLCWFZRTIEO-UHFFFAOYSA-N hexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH3+] XQSBLCWFZRTIEO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229960001922 sodium perborate Drugs 0.000 claims description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 3
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000005068 transpiration Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The formulation, for skin treatment, comprises a major proportion by weight of boric acid and/or a perborate salt, an anti-bacterial amount of a cetyl ammonium bromide salt, a cellulosic vehicle, and a minor amount of at least one sodium salt.
Description
Skin Treatment Formulations
The present invention is concerned with skin treatment formulations. Many skin treatment formulations have been employed over the years. Because of the many types of skin complaints and the variation in individuals response to such formulations, a wide range of such formulations is needed.
For example, the condition known as bromidrosis is associated with excessive foot transpiration, and results in unpleasant foot odours; the condition is due to certain micro-organisms which break down the fatty constituents of unevaporated perspiration, which liberates butyric acid (the latter being the source of the unpleasant smell).
I have now devised a skin care formulation, which in one embodiment is effective in treating bromidrosis, and in another embodiment is effective in treating acne. The formulation according to the invention comprises a major proportion by weight of boric acid and/or a perborate salt, an anti bacterial amount of a cetyl ammonium bromide salt, a cellulosic vehicle and a minor amount of one or more sodium salts.
The boric acid and/or perborate salt is typically present in an amount of 60 to 85% by weight (for example 70 to 75%). WEen a perborate salt is used, the latter is preferably sodium perborate. The cetyl ammonium bromide, which is typically cetyl trimethyl ammonium bromide (Cetrimide) is typically present in an amount of 1 to 3% by weight (for example, about 2% by weight).
The cellulosic vehicle, which is typically carboxymethyl cellulose or a sodium salt thereof, is typically present in an amount of from 15 to 30% by weight (for example, about 20 to 25% by weight); the function of this material is as an emulsifier when the formulation is mixed with water, as will be described below.
The sodium salt or salts present in the formulation according to the invention are, for example, sodium chloride and sodium borate, typically in amounts of 3 to 4% by weight, and 1 to 25 by weight, respectively.
The formulation according to the invention is typically provided in dry form, for mixing with water (typically sterile water) in an amount such that the formulation is in the form of an emulsion or cream before application to the skin. The formulation according to the invention may contain further physiologically accepteble materials, which may be either pharmacologically active (e.g. a steroid) or substantially inactive (e.g. a sugar).
An exemplary formulation according to the invention for treatment of bromidrosis (Formulation A) consists of 8 solid mixture of 3.6% sodium chloride, 1.3% sodium borate, 71.3% boric acid, 2% Cetrimide and 21.8% carboxymethyl cellulose (all the above percentages being by weight).
Formulation A should be mixed with water (generally sterile water) in an amount of 100 ml per 13 grams of Formulation A.
Ihe use of such a formulation has been found to reduce excessive foot transpiration and eliminate bad foot odours, without blocking the pores of the skin or causing any underisable secondary effects. the dry formulation that is, before addition of water) is inert and stable (being capable of storage without deterioration for two years or more).
An exemplary formulation according to the invention for treatment of acne (Formulation B) is substantially similar to Formulation A, except that the amount of boric acid is reduced to 3.5% by weight, the balance being sodium perborate. Ounce again, this should be mixed with water before use.
Claims (8)
1. A skin treatment formulation which comprises a major
proportion by weight of boric acid and/or a perborate
salt, an anti-bacterial amount of a cetyl ammonium bromide
salt, a cellulosic vehicle, and a minor amount of at least
one sodium salt.
2. A formulation according to claim 1, wherein the boric acid
and perborate together constitute 60 to 855 by weight of
the formulation.
3. A. formulation according to claim 1 or 2, wherein said
perborate comprises sodium perborate.
4. A formulation according to any of claims 1 to 3, wherein
said cetyl ammonium bromide comprises cetyl trimetbyl ammonium bromide.
5. A formulation according to any of claims 1 to 4, wherein
said cellulosic vehicle comprises carboxymethyl cellulose
and/or sodium cerboxymethyl cellulose.
6. A formulation according to any of claims 1 to 5, wherein
said sodium salt comprises sodium chloride and/or sodium
borate.
7. A formulation according to any of claims 1 to 6, which is
in the form of a dry mix.
8. For use in the treatment of bromidrosis, a formulation
according to any of claims 1 to 7.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8804531A GB2215205A (en) | 1988-02-26 | 1988-02-26 | Skin treatment formulations comprising boric acid and/or perborate salt |
| AU34344/89A AU3434489A (en) | 1988-02-26 | 1989-02-27 | Skin treatment formulations |
| PCT/GB1989/000198 WO1989007933A2 (en) | 1988-02-26 | 1989-02-27 | Skin treatment formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8804531A GB2215205A (en) | 1988-02-26 | 1988-02-26 | Skin treatment formulations comprising boric acid and/or perborate salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8804531D0 GB8804531D0 (en) | 1988-03-30 |
| GB2215205A true GB2215205A (en) | 1989-09-20 |
Family
ID=10632435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8804531A Withdrawn GB2215205A (en) | 1988-02-26 | 1988-02-26 | Skin treatment formulations comprising boric acid and/or perborate salt |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3434489A (en) |
| GB (1) | GB2215205A (en) |
| WO (1) | WO1989007933A2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2284762A (en) * | 1993-12-17 | 1995-06-21 | Graham Anthony Hill | Deodourant foot powder |
| EP0676191A3 (en) * | 1994-02-22 | 1996-08-28 | Curtis Helene Ind Inc | Deodorant antiperspirant compositions. |
| EP0676193A3 (en) * | 1994-02-22 | 1996-08-28 | Curtis Helene Ind Inc | Topical effect compositions. |
| WO2004007559A1 (en) | 2002-07-10 | 2004-01-22 | Akzo Nobel N.V. | Depolymerization of water soluble polysaccharides |
| EP1206269A4 (en) * | 1999-06-30 | 2007-09-12 | Don H Girvan | Compositions and methods for the treatment of skin disorders |
| EP4178588A4 (en) * | 2020-07-09 | 2023-12-20 | Aliya Pharmaceuticals Inc. | ANTICANCER EFFECT OF PERBORATE SALTS |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4441483C1 (en) * | 1994-11-22 | 1996-04-04 | Gsf Forschungszentrum Umwelt | Use of bio-assimilated boron cpds. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1066795A (en) * | 1963-10-15 | 1967-04-26 | Hollichem Corp | Compositions comprising biocidal quaternary ammonium benzosulfimides |
| US3402242A (en) * | 1964-07-20 | 1968-09-17 | Parachlor Chemical Corp | Non-irritant quaternary ammonium compound composition |
| US3852210A (en) * | 1972-08-11 | 1974-12-03 | Flow Pharma Inc | Stable liquid detergent concentrates containing active oxygen |
| FI780440A7 (en) * | 1978-01-12 | 1979-07-13 | Unilever Nv | DETERGENT COMPOSITION |
| FR2513879A1 (en) * | 1981-10-02 | 1983-04-08 | Olivier Georges | Hygiene prod. esp. feet, controls perspiration and odour - contains antibacterial, antifungal, antiperspirant, deodorant, absorbent, astringent, emollient, moistener, nutrients etc. |
| DE3339196A1 (en) * | 1983-10-28 | 1985-05-09 | Dr. Thilo & Co GmbH, 8029 Sauerlach | Antimicrobial preservative and disinfectant |
-
1988
- 1988-02-26 GB GB8804531A patent/GB2215205A/en not_active Withdrawn
-
1989
- 1989-02-27 AU AU34344/89A patent/AU3434489A/en not_active Abandoned
- 1989-02-27 WO PCT/GB1989/000198 patent/WO1989007933A2/en not_active Ceased
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2284762A (en) * | 1993-12-17 | 1995-06-21 | Graham Anthony Hill | Deodourant foot powder |
| EP0676191A3 (en) * | 1994-02-22 | 1996-08-28 | Curtis Helene Ind Inc | Deodorant antiperspirant compositions. |
| EP0676193A3 (en) * | 1994-02-22 | 1996-08-28 | Curtis Helene Ind Inc | Topical effect compositions. |
| EP1206269A4 (en) * | 1999-06-30 | 2007-09-12 | Don H Girvan | Compositions and methods for the treatment of skin disorders |
| WO2004007559A1 (en) | 2002-07-10 | 2004-01-22 | Akzo Nobel N.V. | Depolymerization of water soluble polysaccharides |
| EP1521777A1 (en) * | 2002-07-10 | 2005-04-13 | Akzo Nobel N.V. | Depolymerization of water soluble polysaccharides |
| EP4178588A4 (en) * | 2020-07-09 | 2023-12-20 | Aliya Pharmaceuticals Inc. | ANTICANCER EFFECT OF PERBORATE SALTS |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8804531D0 (en) | 1988-03-30 |
| WO1989007933A2 (en) | 1989-09-08 |
| AU3434489A (en) | 1989-09-22 |
| WO1989007933A3 (en) | 1989-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1319605C (en) | Virucidal agent having wide-spectrum activity | |
| EP0129003B2 (en) | Cosmetic and dermatological compositions containing 1-alpha-hydroxycholecalciferol | |
| US4395398A (en) | Dental hemostatic composition | |
| US4794106A (en) | Cream | |
| US4224319A (en) | Antiseptic composition for topical application to the skin | |
| US5137718A (en) | Infection fighting composition for topical application | |
| HU198123B (en) | Deodorant and antibacterial cosmetic | |
| USRE33107E (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
| US4269835A (en) | Nasal composition for relieving nasal distress | |
| GB2215205A (en) | Skin treatment formulations comprising boric acid and/or perborate salt | |
| IE46872B1 (en) | Dithranol composition for the treatment of psoriasis | |
| EP0124147A1 (en) | Spironolactone containing composition for combating acne | |
| CA1238276A (en) | Betamethasone dipropionate cream | |
| US6221403B1 (en) | Topical composition | |
| US5886038A (en) | Composition and method for treatment of psoriasis | |
| GB2068225A (en) | Dermatological compositions containing hydrogen peroxide | |
| DE69108964T2 (en) | Preparation containing antifungal imidazole for external use. | |
| US4364945A (en) | Nasal composition for relieving nasal distress | |
| JP3516952B2 (en) | Topical composition for medical use | |
| JPH03120230A (en) | Percutaneous absorbefacient of drug active ingredient and percutaneous absorption type pharmaceutical | |
| US6469070B1 (en) | Topical medicament comprising phenolic biocide and choline | |
| US3019162A (en) | Cinchophen-hydrocortisone topical compositions | |
| GB2050831A (en) | Corticosteroid stick formulations | |
| GB2330773A (en) | A skin-moisturising preparation containing an anti-bacterial agent | |
| US2381262A (en) | Medicament vehicles or emulsions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |